ClinicalTrials.gg
CompletedNCT00658775Updated Dec 21, 2015Results posted

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

A Phase 3 interventional study of Rabeprazole sodium and Esomeprazole in Gastroesophageal Reflux Disease (GERD), sponsored by Eisai Inc.. Completed at 83 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-12-21.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,069
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
3rd of 39
1,069 · median 100
Started
2008
with 7 others
Phase 3
16 of 40
none open now
Registered
19th of 40
by date
Lead sponsor
9 of 40
Eisai Inc.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 3rd largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2008, is one of 16 in phase 3, and was the 19th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

Read the detailed description

This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • GERD
  • erosive GERD
  • erosive esophagitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY INCLUSION CRITERIA:

  1. Male or female, ages 18 to 75 years.
  2. History of GERD symptoms for at least 3 months immediately before screening.
  3. Heartburn for at least 2 days a week for at least 1 month before screening.
  4. Esophageal erosions of LA Grades C or D based on EGD taken within 14 days prior to enrollment.
  5. Subjects who are H. pylori negative based on a screening test.
  6. Females should be either of non- or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of .
  7. Subjects must be able to read, write, and understand the language of the symptom diary.

KEY EXCLUSION CRITERIA:

  1. Current or a history of esophageal motility disorders.
  2. Current or a history of Barrett's esophagus.
  3. Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).
  4. Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.
  5. Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.
  6. Inflammatory bowel disease.
  7. Unstable diabetes mellitus.
  8. History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.
  9. Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral (>= 20 mg/day prednisone or equivalent), or aspirin (> 325 mg/day).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,069 participants (actual)

Study arms

  • Experimental
    1

    Drug: Rabeprazole sodium

  • Active comparator
    2

    Drug: Esomeprazole

Interventions

  • Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.

    Also known as: Aciphex

  • Esomeprazole 40 mg capsule, once daily for 4-8 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

    Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

    Time frame: Baseline and Week 8

  2. Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

    Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

    During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days.

    Time frame: Week 4

07

Results

Posted Jun 23, 2015

Participant flow

Participant flow — Overall Study
MilestoneESO 40mgRAB ER 50mg
Started537528
Completed495485
Not completed4243
Withdrew: Adverse event46
Withdrew: Lost to follow-up1718
Withdrew: Withdrawal by subject64
Withdrew: Withdrawal of consent87
Withdrew: Other78

Outcome measures

SecondaryPercentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days.

Time frame:
Week 4
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
Percentage of ParticipantsESO 40mgRAB ER 50mg
Yes52.553.2
No4039.6
Missing7.47.2
PrimaryPercentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

Time frame:
Baseline and Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
Percentage of ParticipantsESO 40mgRAB ER 50mg
Yes78.477.5
No16.618.4
Missing54.2
PrimaryPercentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.

Time frame:
Baseline and Week 4
Reported as:
Number · Percentage of Participants
Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
Percentage of ParticipantsESO 40mgRAB ER 50mg
Yes50.750.9
No46.447
Missing32.1

Adverse events

Collected over For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to approximately 10 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ESO 40mg—3/532 (0.6%)0/532 (0%)
RAB ER 50mg—3/526 (0.6%)0/526 (0%)
Most frequent serious events
Most frequent serious events
EventESO 40mgRAB ER 50mg
PneumoniaInfections and infestations0/5321/526
Pneumonia primary atypicalInfections and infestations0/5321/526
Head injuryInjury, poisoning and procedural complications0/5321/526
Oesophageal stenosisGastrointestinal disorders1/5320/526
CholecystitisHepatobiliary disorders1/5320/526
Transient ischaemic attackNervous system disorders1/5320/526

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ESO 40mgRAB ER 50mgTotal
Mean49.1 ± 13.3851 ± 12.7950 ± 13.12
Sex: Female, Male
Sex: Female, Male(Participants)ESO 40mgRAB ER 50mgTotal
Female195179374
Male342349691
08

Study locations

83 sites
  • Moline, Illinois 61265, United States
  • Buenos Aires, BUE B1832BQS, Argentina
  • Buenos Aires, BUE C1117ABK, Argentina
  • Ciudad Autonoma de Bs. As., CBA 1431, Argentina
  • Ciudad Autonoma de Bs. As., CBA C1120AAT, Argentina
  • Ciudad Autonoma de Bs. As., CBA C1181ACH, Argentina
  • Rosario, SFE 2000, Argentina
  • San Miguel de Tucuman, TUC 4000, Argentina
  • La Plata, 1900, Argentina
  • Penrith, New South Wales 2751, Australia
  • Caboolture, Queensland 4510, Australia
  • Adelaide, South Australia 5001, Australia
  • Woodville, South Australia 5011, Australia
  • Launceston, Tasmania 7250, Australia
  • Ballarat, Victoria 3353, Australia
  • Fitzroy, Victoria 3065, Australia
  • Haskovo, 6300, Bulgaria
  • Plovdiv, 4000, Bulgaria
  • Rousse, 7002, Bulgaria
  • Sofia, 1527, Bulgaria
  • Sofia, 1606, Bulgaria
  • Barrie, Ontario L4M 7G1, Canada
  • Chatham, Ontario N7L 1B9, Canada
  • Hamilton, Ontario L8V 1C3, Canada
  • Richmond Hill, Ontario L4B 3P8, Canada
  • Sarnia, Ontario N7T 4X3, Canada
  • Toronto, Ontario M3J 1N2, Canada
  • Toronto, Ontario M3N 2V7, Canada
  • Toronto, Ontario M4P 1P2, Canada
  • Toronto, Ontario M9W 4L6, Canada
  • Sherbrooke, Quebec J1G 2E8, Canada
  • Saskatoon, Saskatchewan S7K 1N4, Canada
  • Providencia, Chile
  • Santiago, Chile
  • Temuco, Chile
  • Osijek, 31 000, Croatia
  • Split, 21 000, Croatia
  • Zagreb, 10 000, Croatia
  • Tallinn, 10138, Estonia
  • Tallinn, 10617, Estonia
  • Lyon Cedex 3, Lyonnais 69437, France
  • Marseille, Provence 13015, France
  • Saint-Quentin 2, 2100, France
  • Potsdam, BR 14482, Germany
  • Freising, BY 85356, Germany
  • Herne, NW 44623, Germany
  • Muenster, NW 48167, Germany
  • Ludwigshafen, RP 67067, Germany
  • Mainz, RP 55131, Germany
  • Dresden, SN 1307, Germany
  • Wolmirstedt, ST 39326, Germany
  • Balatonfured, 8230, Hungary
  • Budapest, 1088, Hungary
  • Budapest, 1201, Hungary
  • Debrecen, 4032, Hungary
  • Eger, 3300, Hungary
  • Gyor, 9024, Hungary
  • Gyula, 5700, Hungary
  • Kaposvar, 7400, Hungary
  • Pecs, 7624, Hungary
  • Siofok, 8601, Hungary
  • Szekszard, 7100, Hungary
  • Hyderabad, Andhra Pradesh 500 082, India
  • Hyderabad, Andhra Pradesh 500001, India
  • Hyderabad, Andhra Pradesh 500004, India
  • Hyderabad, Andhra Pradesh 500012, India
  • Hyderabad, Andhra Pradesh 500063, India
  • Hyderabad, Andhra Pradesh 500082, India
  • Secunderabad, Andhra Pradesh 500003, India
  • Vishakapatnam, Andhra Pradesh 53002, India
  • New Delhi, Delhi 110029, India
  • Bangalore, Karnataka 560054, India
  • Mangalore, Karnataka 575001, India
  • Cochin, Kerala 682304, India
  • Ludhiana, Punjab 141001, India
  • Chennai, Tamilnadu 600096, India
  • Madurai, Tamilnadu 625002, India
  • Balvi, LV-4501, Latvia
  • Daugavpils, LV-5417, Latvia
  • Riga, LV-1006, Latvia
  • Siauliai, LT-76231, Lithuania
  • Vilnius, 3215, Lithuania
  • Vilnius, LT-08661, Lithuania
09

References and documents

Publications

  • Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. Aliment Pharmacol Ther. 2011 Jan;33(2):203-12. doi: 10.1111/j.1365-2036.2010.04516.x. Epub 2010 Nov 30. PubMed 21114792 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Sep 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2008
First posted
Apr 15, 2008
Start
Feb 2008
Primary completionActual
Sep 2009
CompletionActual
Jan 2010
Results first posted
Jun 23, 2015
Last update
Dec 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00658775
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Apr 15, 2008
Start date
Feb 2008
Primary completion
Sep 2009
Completion
Jan 2010
Results posted
Jun 23, 2015
Last update
Dec 21, 2015

Study contacts

Yufang Lu
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion